Acute Lymphoblastic Leukemia Clinical Trial
Official title:
A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL)
Verified date | February 2021 |
Source | Therapeutic Advances in Childhood Leukemia Consortium |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study.
Status | Terminated |
Enrollment | 9 |
Est. completion date | September 23, 2009 |
Est. primary completion date | May 19, 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 21 Years |
Eligibility | Inclusion Criteria 1. Age Patients must be < 21 years of age when enrolled onto this study. T2005-001 Protocol version 6/27/2007 17 2. Diagnosis Patients must have relapsed or refractory ALL with a M3 marrow (marrow blasts >25%) without clinical evidence of testicular disease or laboratory evidence of CNS disease defined as CSF WBC > 5 cells/microliter and blasts. (See Appendix I for method of evaluating traumatic lumbar punctures.) Patients in early first relapse (defined as a patient who relapses less than 36 months from their initial remission [CR1]) are eligible for the phase I portion of the trial. 3. Performance Level Karnofsky > 60% for patients > 10 years of age and Lansky > 60% for patients < 10 years of age. 4. Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study. 1. Prior anthracycline exposure: Patients must have less than 300mg/m2 lifetime exposure of anthracycline chemotherapy. (See Appendix III for calculation criteria) 2. Stem Cell Transplant (SCT): Patients are eligible 6 months after allogeneic stem cell transplant as long as patients are not actively being treated for graft-versus-host-disease (GvHD). 3. During the phase I portion of the trial, there is no limit on the number of prior treatment regimens. 4. During the phase II portion of the trial, patients must have had two or more prior therapeutic attempts defined as: - Persistent initial disease after two induction attempts, or - Relapse after one-reinduction attempt (2nd relapse), or - Persistent disease after first relapse and initial re-induction attempt (Patients in any first relapse are not eligible for the phase II portion of the study) 5. During the phase II portion of the trial, patients must have no more than 3 prior therapeutic attempts and it must be at least 6 months since the last treatment with a "VPLD" induction/re-induction regimen. 5. Reproductive Function 1. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment and within 48 hours of starting therapy. 2. Female patients with infants must agree not to breastfeed their infants while on this study. 3. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for 3 months following completion of therapy. Exclusion Criteria 1. Drug Allergies Patients will be excluded if they have allergies to the following drugs: - Asparaginase products - Sulfa containing medications 2. Renal Function Patients will be excluded if their serum creatinine is > the upper limit of normal (ULN) for age at the institution's laboratory. 3. Liver/Pancreatic Function 1. Direct bilirubin > 1.5x the institutional ULN for age. A total bilirubin result that is less than 1.5 times the institutional ULN for age may be used for eligibility if a direct bilirubin result is not available. 2. SGPT (ALT) > 4 x institutional ULN 3. Grade 3 or greater pancreatitis as defined by the CTCAE v3.0 4. Amylase or Lipase > 2 x institutional ULN 4. Cardiac Function Patients will be excluded if their shortening fraction by echocardiogram is less than 30%. 5. Infection Patients will be excluded if they have an active, uncontrolled infection. 1. Patients with grade 2 or greater motor or sensory neuropathy per CTC 3.0 criteria. 2. Patients with grade 2 or greater Ileus (neuroconstipation) per CTC 3.0 criteria. 3. Patients currently being treated with coumadin. 4. Patients currently being treated with colchicines. 5. Patients planning on receiving other investigational agents while on this study. (An investigational agent is defined as any drug not currently approved for use in humans.) 6. Patients planning on receiving other anti-cancer therapies while on this study. 7. Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study. 8. Patients who, based on BSA and current dose level, require a daily dose of ABT-751 that is less than 25mg per day. 9. Patients who have started protocol therapy prior to enrollment. Patient may still enroll if IT Ara-C or IT MTX were given within 48 hours of study enrollment as part of the diagnostic lumbar procedure. These patients will not participate in the CSF PK portion of the study. |
Country | Name | City | State |
---|---|---|---|
United States | C.S. Mott Children's Hospital | Ann Arbor | Michigan |
United States | Childrens Hospital Los Angeles | Los Angeles | California |
United States | Stanford University Medical Center | Palo Alto | California |
United States | UCSF School of Medicine | San Francisco | California |
United States | Seattle Children's Hospital | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Therapeutic Advances in Childhood Leukemia Consortium | Abbott |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Patients That Experienced Dose Limiting Toxicity From ABT-751 | ABT-751 was given daily for 21 days for a period of 28 day course in combination with dexamethasone, PEG-asparaginase, and doxorubicin. The occurrence of a dose limiting toxicity (DLT) was evaluated at the end of the 28 day course.
DLT will be defined as any of the following events that are deemed by the investigator as probably or definitely attributable to ABT-751. Toxicity grade follows the CTCAE criteria, version 3.0. A copy of the CTCAE can be downloaded from the CTEP home page (http://ctep.cancer.gov). Grade 3 or 4 Ileus Grade 3 or 4 Constipation Grade 3 or 4 Gastrointestinal obstruction, any location Grade 3 or 4 Sensory Neuropathy Grade 3 or 4 Motor Neuropathy Grade 3 or 4 Neuropathic pain lasting longer than 24 hours despite medical intervention Grade 3 or 4 Hypoxia in the absence of anemia or infection Grade 4 Alanine aminotransferase (ALT) which does not return to |
Each dose level is evaluated | |
Primary | Number of Patients That Achieved Complete Response to ABT-751 | Complete response (CR) is the occurrence of all of the following on approximately Day 29: less than 5% leukemic blasts in the bone marrow aspirate with no evidence of leukemic blasts in the CSF or peripheral blood and recovery of peripheral blood counts of an Absolute neutrophil count (ANC) > 750/µL and Platelet count > 75,000 µL. | Day 29 of Course 1 | |
Secondary | Number of Patients With Occurrence of Toxic Death | The occurrence of toxic death at anytime that is definitely, probably or possibly related to the treatment. | From the first dose of study therapy until 30 days after last therapy dose. Last dose protocol therapy is on day 21. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |